Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2047 • ACR Convergence 2020
Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas³, Karishma Rupani⁴, Gerald Watts⁵, Kevin Wei¹, Runci Wang⁴, Deepak Rao⁴, Accelerating Medicines Partnership (AMP) - RA/SLE⁶, Soumya Raychaudhuri² and Michael Brenner¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigam and Women's Hospital, Boston, ⁶., Boston
Background/Purpose: T cell-derived pro-inflammatory cytokines are major drivers of RA pathogenesis, and these cytokines have traditionally been attributed to CD4 T cells. However, single-cell RNA-sequencing…
Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Cristiano Moura¹, Marina Machado¹, Celline Almeida-Brasil¹, Jeffrey R Curtis², Kevin Winthrop³, Michal Abrahamowicz¹ and Sasha Bernatsky⁴, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Oregon Health & Science University, Portland, OR, ⁴The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
Abstract Number: 0067 • ACR Convergence 2020
Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Rheumatoid Arthritis via STAT3
Mary Canavan¹, Viviana Marzaioli¹, Vipul Bhargava², Sunil Nagpal³, Phil Gallagher⁴, Conor Hurson⁵, Ronan Mullan⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ²Janssen Research & Development, Springhouse, PA, ³Janssen Research & Development, Collegeville, PA, ⁴St Vincents University Hospital, UCD, Dublin, Ireland, ⁵St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁶Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Myeloid Dendritic Cells (DC) are potent antigen presenting cells that can be subdivided into CD141+ and CD1c+ DC. We have previously reported an unacknowledged…
Abstract Number: 0138 • ACR Convergence 2020
Alignment and Discordances in Treatment Perceptions and Shared Decision-Making Among RA Patients and Rheumatology Care Teams
Robert Levin¹, Christopher Parker², Kostas Botsoglou³, Jigar Shah⁴, Nimesh Dayal⁵, Kristina Fajardo⁶, Laura Simone⁶, Jeff Carter⁶ and Tamar Sapir⁶, ¹University of South Florida, Clearwater, FL, ²Austin Diagnostic Clinic, Austin, TX, ³Rheumatology Center WNY, Buffalo, NY, ⁴Arthritis and Rheumatology Center of South Florida, Margate, FL, ⁵Arthritis Center of Orlando, Ocoee, FL, ⁶PRIME Education, LLC, Fort Lauderdale, FL
Background/Purpose: Evidence-based guidelines for rheumatoid arthritis (RA) call for shared decision-making (SMD) as a method to personalize treatment decisions and achieve treat-to-target goals. We assessed alignment…
Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0211 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
Xiaofeng Zeng¹, Dongbao Zhao², Sebastiao Radominski³, Mauro Keiserman⁴, Chang Keun Lee⁵, Sebastian Meerwein⁶, Jeffrey Enejosa⁷, Yunxia Sui⁷, Mohamed-Eslam Mohamed⁷ and Won Park⁸, ¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²Shanghai Changhai Hospital, Shanghai, China (People's Republic), ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Pontificial Catholic University, Porto Alegre, Brazil, ⁵Asan Medical Center, Seoul, Republic of Korea, ⁶Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸Inha University, Incheon, Republic of Korea
Background/Purpose: This Phase 3, randomized, double-blind, placebo (PBO)-controlled study assessed the efficacy and safety of upadacitinib (UPA) in combination with csDMARDs in patients with rheumatoid…
Abstract Number: 0228 • ACR Convergence 2020
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Eduardo Mysler¹, Yoshiya Tanaka², Arthur Kavanaugh³, Daniel Aletaha⁴, Peter Taylor⁵, In-Ho Song⁶, Tim Shaw⁶, Yanna Song⁷, Ryan DeMasi⁶, Mira Ali⁶ and Roy Fleischmann⁸, ¹Organización Medica de Investigación, Buenos Aires, Argentina, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁵Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the randomized, double-blinded, Phase 3 SELECT-COMPARE study, upadacitinib (UPA) + MTX demonstrated greater clinical and functional responses vs adalimumab (ADA) + MTX in…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Sebastian Sattui¹, Iris Navarro-Millan², Fenglong Xie³, Mangala Rajan², Huifeng Yun⁴ and Jeffrey R Curtis⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Bonnia Liu¹, Victor Yang², Christopher McMaster³, Russell Buchanan⁴, Albert Frauman⁵ and David Liew⁶, ¹Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, ²Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ⁶Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
Abstract Number: 0753 • ACR Convergence 2020
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
Stéphanie de Montjoye¹, Tatiana Sokolova¹, Emilie Sapart¹, Bernard Lauwerys², Stéphanie Dierckx³, Christine Galant⁴, Laurent Meric de Bellefon¹, Adrien Nzeusseu Toukap⁵, Clément Triaille⁶ and Patrick Durez⁷, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ⁴3Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁵1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
Abstract Number: 0770 • ACR Convergence 2020
Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
Ashley Curran¹, Jonathan Crawford¹ and Erika Darrah¹, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Citrullinated proteins are hallmark targets of the autoimmune response in rheumatoid arthritis (RA), but the mechanism by which immune tolerance is broken to these self-proteins…
Abstract Number: 0789 • ACR Convergence 2020
Matrix Gla Protein (MGP) Modified with Malondialdehyde/Acetaldehyde Is Increased in Rheumatoid Arthritis and Cardiovascular Patients
Xiarepati Tieliwaerdi¹, Nozima Aripova¹, Michael Duryee¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Daniel Anderson¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased cardiovascular disease (CVD) burden, dramatically increasing the risk of mortality. Circulating antibodies to Malondialdehyde-Acetaldehyde (MAA) modified…
Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].